QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.103671v1 318/3/956    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, F.-Q. Articles by Vitek, M. P. Search for Related Content PubMed PubMed Citation Articles by Li, F.-Q. Articles by Vitek, M. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Multiple Sclerosis Hazardous Substances DB NITRIC OXIDE

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Apolipoprotein E-Derived Peptides Ameliorate Clinical Disability and Inflammatory Infiltrates into the Spinal Cord in a Murine Model of Multiple Sclerosis

Division of Neurology, Department of Medicine (F.-Q.L., D.T.L., C.A.C., M.P.V.), Human Vaccine Institute (G.D.S.), Duke University Medical Center, Durham, North Carolina; and Cognosci, Inc., Research Triangle Park, North Carolina (S.E.M.)

Apolipoprotein E (apoE), well known to play a role in lipid transport and cholesterol metabolism, also exerts anti-inflammatory and neuroprotective effects in the central nervous system. Recent clinical and genetic studies display an association between apoE genotype (APOE) and the progression and severity of multiple sclerosis, raising the possibility that modulation of apoE may be a novel treatment for multiple sclerosis. Using a murine experimental autoimmune encephalomyelitis (EAE) model of human multiple sclerosis, we found that a peptidomimetic of apoE protein, COG133, substantially reduces the clinical symptoms of EAE and promotes remission from the disability when administered before or after onset of disease. Most notably, fusion of COG133 to a protein transduction domain creates COG112, a modified apoE-mimetic peptide with significantly enhanced anti-inflammatory bioactivities in vitro, and improved therapeutic effects on EAE in vivo, which renders a nearly full remission from the disability. Histopathological analysis showed that COG112 and COG133 attenuated demyelination and significantly diminished the number of peripheral cells infiltrating into the spinal cord. ApoE mimetics also interfered with several mechanisms relevant to the pathogenesis of EAE and multiple sclerosis, including activation of macrophages, subsequent production of nitric oxide and inflammatory cytokines, and lymphocyte proliferation. These data suggest that apoE mimetics represent a multidimensional therapeutic for multiple sclerosis capable of inhibiting the inflammatory cascade, modulating immune cell function, and reducing clinical signs, which may have novel utility for the treatment of inflammatory autoimmune diseases.

Address correspondence to: Dr. Feng-Qiao Li, Division of Neurology, Box 2900, Duke University Medical Center, Durham, NC 27710. E-mail: fengqiao.li{at}duke.edu

This article has been cited by other articles:

				E. A. Gay, R. C. Klein, M. A. Melton, P. J. Blackshear, and J. L. Yakel Inhibition of Native and Recombinant Nicotinic Acetylcholine Receptors by the Myristoylated Alanine-Rich C Kinase Substrate Peptide J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 884 - 890. [Abstract] [Full Text] [PDF]

				K. Singh, R. Chaturvedi, M. Asim, D. P. Barry, N. D. Lewis, M. P. Vitek, and K. T. Wilson The Apolipoprotein E-mimetic Peptide COG112 Inhibits the Inflammatory Response to Citrobacter rodentium in Colonic Epithelial Cells by Preventing NF-{kappa}B Activation J. Biol. Chem., June 13, 2008; 283(24): 16752 - 16761. [Abstract] [Full Text] [PDF]

				E. A. Gay, R. J. Bienstock, P. W. Lamb, and J. L. Yakel Structural Determinates for Apolipoprotein E-Derived Peptide Interaction with the {alpha}7 Nicotinic Acetylcholine Receptor Mol. Pharmacol., October 1, 2007; 72(4): 838 - 849. [Abstract] [Full Text] [PDF]